OncoMatch/Clinical Trials/NCT06414902
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Is NCT06414902 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ArabinoFuranosylGuanine [18F]F-AraG for esophageal cancer.
Treatment: ArabinoFuranosylGuanine [18F]F-AraG — To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Prior therapy
Lab requirements
Kidney function
eGFR < 40 within 1 month prior to receiving 8F-FAraG [excluded]
eGFR<40 within 1 month prior to receiving 8F-FAraG
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06414902 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages